Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors.

Agresti R, Triulzi T, Sasso M, Ghirelli C, Aiello P, Rybinska I, Campiglio M, Sfondrini L, Tagliabue E, Bianchi F.

Cells. 2019 Feb 19;8(2). pii: E181. doi: 10.3390/cells8020181.

2.

Presynaptic α2δ-2 calcium channel subunits regulate postsynaptic GABAA-receptor abundance and axonal wiring.

Geisler S, Schöpf CL, Stanika R, Kalb M, Campiglio M, Repetto D, Traxler L, Missler M, Obermair GJ.

J Neurosci. 2019 Jan 25. pii: 2234-18. doi: 10.1523/JNEUROSCI.2234-18.2019. [Epub ahead of print]

PMID:
30683685
3.

Correcting the R165K substitution in the first voltage-sensor of CaV1.1 right-shifts the voltage-dependence of skeletal muscle calcium channel activation.

El Ghaleb Y, Campiglio M, Flucher BE.

Channels (Austin). 2019 Dec;13(1):62-71. doi: 10.1080/19336950.2019.1568825.

4.

STAC proteins: The missing link in skeletal muscle EC coupling and new regulators of calcium channel function.

Flucher BE, Campiglio M.

Biochim Biophys Acta Mol Cell Res. 2018 Dec 10. pii: S0167-4889(18)30523-8. doi: 10.1016/j.bbamcr.2018.12.004. [Epub ahead of print] Review.

5.

An innovative approach to evaluate preeclampsia risk in the first trimester of pregnancy.

Turdo F, Boatti L, Mignone F, Moretti F, Campiglio M, Colosi E.

Minerva Ginecol. 2018 Oct;70(5):641-642. doi: 10.23736/S0026-4784.18.04275-2. No abstract available.

PMID:
30293401
6.

STAC3 incorporation into skeletal muscle triads occurs independent of the dihydropyridine receptor.

Campiglio M, Kaplan MM, Flucher BE.

J Cell Physiol. 2018 Dec;233(12):9045-9051. doi: 10.1002/jcp.26767. Epub 2018 Aug 2.

7.

Role of putative voltage-sensor countercharge D4 in regulating gating properties of CaV1.2 and CaV1.3 calcium channels.

Costé de Bagneaux P, Campiglio M, Benedetti B, Tuluc P, Flucher BE.

Channels (Austin). 2018;12(1):249-261. doi: 10.1080/19336950.2018.1482183.

8.

The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.

Forte L, Turdo F, Ghirelli C, Aiello P, Casalini P, Iorio MV, D'Ippolito E, Gasparini P, Agresti R, Belmonte B, Sozzi G, Sfondrini L, Tagliabue E, Campiglio M, Bianchi F.

BMC Cancer. 2018 May 23;18(1):586. doi: 10.1186/s12885-018-4500-9.

9.

STAC proteins associate to the IQ domain of CaV1.2 and inhibit calcium-dependent inactivation.

Campiglio M, Costé de Bagneaux P, Ortner NJ, Tuluc P, Van Petegem F, Flucher BE.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1376-1381. doi: 10.1073/pnas.1715997115. Epub 2018 Jan 23.

10.

Molecular mimicking of C-terminal phosphorylation tunes the surface dynamics of CaV1.2 calcium channels in hippocampal neurons.

Folci A, Steinberger A, Lee B, Stanika R, Scheruebel S, Campiglio M, Ramprecht C, Pelzmann B, Hell JW, Obermair GJ, Heine M, Di Biase V.

J Biol Chem. 2018 Jan 19;293(3):1040-1053. doi: 10.1074/jbc.M117.799585. Epub 2017 Nov 27.

11.

Structural insights into binding of STAC proteins to voltage-gated calcium channels.

Wong King Yuen SM, Campiglio M, Tung CC, Flucher BE, Van Petegem F.

Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9520-E9528. doi: 10.1073/pnas.1708852114. Epub 2017 Oct 23.

12.

Stapled Voltage-Gated Calcium Channel (CaV) α-Interaction Domain (AID) Peptides Act As Selective Protein-Protein Interaction Inhibitors of CaV Function.

Findeisen F, Campiglio M, Jo H, Abderemane-Ali F, Rumpf CH, Pope L, Rossen ND, Flucher BE, DeGrado WF, Minor DL Jr.

ACS Chem Neurosci. 2017 Jun 21;8(6):1313-1326. doi: 10.1021/acschemneuro.6b00454. Epub 2017 Mar 17.

13.

STAC3 stably interacts through its C1 domain with CaV1.1 in skeletal muscle triads.

Campiglio M, Flucher BE.

Sci Rep. 2017 Jan 23;7:41003. doi: 10.1038/srep41003.

14.

Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor.

Le Noci V, Sommariva M, Tortoreto M, Zaffaroni N, Campiglio M, Tagliabue E, Balsari A, Sfondrini L.

Oncoimmunology. 2016 Sep 20;5(11):e1234571. doi: 10.1080/2162402X.2016.1234571. eCollection 2016.

15.

Splice variants of the CaV1.3 L-type calcium channel regulate dendritic spine morphology.

Stanika R, Campiglio M, Pinggera A, Lee A, Striessnig J, Flucher BE, Obermair GJ.

Sci Rep. 2016 Oct 6;6:34528. doi: 10.1038/srep34528.

16.

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.

Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, Forte L, Casalini P, Aiello P, Sfondrini L, Agresti R, Carcangiu ML, Plantamura I, Sozzi G, Tagliabue E, Campiglio M.

Oncotarget. 2016 Oct 25;7(43):69649-69665. doi: 10.18632/oncotarget.11935.

17.

A Cav3.2/Stac1 molecular complex controls T-type channel expression at the plasma membrane.

Rzhepetskyy Y, Lazniewska J, Proft J, Campiglio M, Flucher BE, Weiss N.

Channels (Austin). 2016 Sep 2;10(5):346-354. Epub 2016 May 5.

18.

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.

Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E.

Oncotarget. 2015 Sep 29;6(29):28173-82. doi: 10.18632/oncotarget.4405.

19.

The role of auxiliary subunits for the functional diversity of voltage-gated calcium channels.

Campiglio M, Flucher BE.

J Cell Physiol. 2015 Sep;230(9):2019-31. doi: 10.1002/jcp.24998. Review.

20.

Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells.

Bianchi F, Sasso M, Turdo F, Beretta GL, Casalini P, Ghirelli C, Sfondrini L, Ménard S, Tagliabue E, Campiglio M.

J Cell Physiol. 2015 Nov;230(11):2661-70. doi: 10.1002/jcp.24968.

PMID:
25711523
21.

"Omics" and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas.

Tagliabue E, Campiglio M.

Front Oncol. 2014 Nov 18;4:334. doi: 10.3389/fonc.2014.00334. eCollection 2014. No abstract available.

22.

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens.

Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, Dotti KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, Pietrantonio F.

Cancers (Basel). 2014 Aug 29;6(3):1753-68. doi: 10.3390/cancers6031753.

23.

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.

Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini PL, Triulzi T, Menard S, Nanni P, Tagliabue E, Pupa SM.

Cancer Res. 2014 Nov 1;74(21):6248-59. doi: 10.1158/0008-5472.CAN-14-0983. Epub 2014 Aug 27.

24.
25.

PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.

Plantamura I, Casalini P, Dugnani E, Sasso M, D'Ippolito E, Tortoreto M, Cacciatore M, Guarnotta C, Ghirelli C, Barajon I, Bianchi F, Triulzi T, Agresti R, Balsari A, Campiglio M, Tripodo C, Iorio MV, Tagliabue E.

Mol Oncol. 2014 Jul;8(5):968-81. doi: 10.1016/j.molonc.2014.03.015. Epub 2014 Mar 27.

26.

Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab.

Campiglio M, Sandri M, Sasso M, Bianchi F, Balsari A, Ménard S, Tagliabue E.

Ann Oncol. 2014 May;25(5):1073-4. doi: 10.1093/annonc/mdu058. Epub 2014 Feb 20. No abstract available.

PMID:
24558025
27.

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study.

Campiglio M, Bufalino R, Sasso M, Ferri E, Casalini P, Adamo V, Fabi A, Aiello R, Riccardi F, Valle E, Scotti V, Tabaro G, Giuffrida D, Tarenzi E, Bologna A, Mustacchi G, Bianchi F, Balsari A, Ménard S, Tagliabue E.

Breast Cancer Res Treat. 2013 Aug;141(1):101-10. doi: 10.1007/s10549-013-2658-z. Epub 2013 Aug 13.

28.

Stable incorporation versus dynamic exchange of β subunits in a native Ca2+ channel complex.

Campiglio M, Di Biase V, Tuluc P, Flucher BE.

J Cell Sci. 2013 May 1;126(Pt 9):2092-101. doi: 10.1242/jcs.jcs124537. Epub 2013 Feb 27.

29.

PET prediction of response to trastuzumab in ErbB2-positive human xenograft model.

Tagliabue E, Campiglio M, Balsari A, Ménard S.

J Nucl Med. 2012 Oct;53(10):1654-5; author reply 1655-6. doi: 10.2967/jnumed.112.108068. Epub 2012 Aug 23. No abstract available.

30.

The HER2 World: Better Treatment Selection for Better Outcome.

Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S.

J Natl Cancer Inst Monogr. 2011;2011(43):82-5. doi: 10.1093/jncimonographs/lgr041.

PMID:
22043048
31.

Surface traffic of dendritic CaV1.2 calcium channels in hippocampal neurons.

Di Biase V, Tuluc P, Campiglio M, Obermair GJ, Heine M, Flucher BE.

J Neurosci. 2011 Sep 21;31(38):13682-94. doi: 10.1523/JNEUROSCI.2300-11.2011.

32.

Activity and resistance of trastuzumab according to different clinical settings.

Tagliabue E, Campiglio M, Pupa SM, Ménard S, Balsari A.

Cancer Treat Rev. 2012 May;38(3):212-7. doi: 10.1016/j.ctrv.2011.06.002. Epub 2011 Jul 2. Review.

PMID:
21726959
33.

Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.

Campiglio M, Bufalino R, Sandri M, Ferri E, Aiello RA, De Matteis A, Mottolese M, De Placido S, Querzoli P, Jirillo A, Bottini A, Fantini M, Bonetti A, Pedani F, Mauri M, Molino A, Ferro A, Pupa SM, Sasso M, Ménard S, Balsari A, Tagliabue E.

Breast Cancer Res Treat. 2011 Jul;128(1):147-54. doi: 10.1007/s10549-011-1484-4. Epub 2011 Apr 11.

PMID:
21479926
34.

Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.

Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della Mina P, Menard S, Filipazzi P, Rivoltini L, Tagliabue E, Pupa SM.

J Cell Physiol. 2012 Feb;227(2):658-67. doi: 10.1002/jcp.22773.

PMID:
21465472
35.

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.

Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A, Carcangiu ML, Zambetti M, Piazza T, Ferrini S, Ménard S, Tagliabue E, Pupa SM.

J Cell Physiol. 2010 Oct;225(1):256-65. doi: 10.1002/jcp.22257.

PMID:
20506359
36.

HER2 as a target for breast cancer therapy.

Tagliabue E, Balsari A, Campiglio M, Pupa SM.

Expert Opin Biol Ther. 2010 May;10(5):711-24. doi: 10.1517/14712591003689972. Review.

PMID:
20214497
37.

Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.

De Cesare M, Sfondrini L, Campiglio M, Sommariva M, Bianchi F, Perego P, van Rooijen N, Supino R, Rumio C, Zunino F, Pratesi G, Tagliabue E, Balsari A.

J Immunother. 2010 Jan;33(1):8-15. doi: 10.1097/CJI.0b013e3181affaa7.

PMID:
19952960
38.

Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation.

Haines E, Minoo P, Feng Z, Resalatpanah N, Nie XM, Campiglio M, Alvarez L, Cocolakis E, Ridha M, Di Fulvio M, Gomez-Cambronero J, Lebrun JJ, Ali S.

Mol Cell Biol. 2009 May;29(10):2505-20. doi: 10.1128/MCB.00034-09. Epub 2009 Mar 9.

39.

BHLHB3: a candidate tumor suppressor in lung cancer.

Falvella FS, Colombo F, Spinola M, Campiglio M, Pastorino U, Dragani TA.

Oncogene. 2008 Jun 12;27(26):3761-4. doi: 10.1038/sj.onc.1211038. Epub 2008 Jan 28.

PMID:
18223678
40.

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.

Normanno N, Campiglio M, Maiello MR, De Luca A, Mancino M, Gallo M, D'Alessio A, Menard S.

Breast Cancer Res Treat. 2008 Nov;112(1):25-33. Epub 2007 Nov 30.

PMID:
18060492
41.

Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification.

Magnifico A, Albano L, Campaner S, Campiglio M, Pilotti S, Ménard S, Tagliabue E.

Cancer Res. 2007 Jun 1;67(11):5308-17.

42.

Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections.

Bianchi F, Tagliabue E, Ménard S, Campiglio M.

Cell Cycle. 2007 Mar 15;6(6):643-6. Epub 2007 Mar 20. Review.

PMID:
17374991
43.

FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells.

Bianchi F, Magnifico A, Olgiati C, Zanesi N, Pekarsky Y, Tagliabue E, Croce CM, Ménard S, Campiglio M.

Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18981-6. Epub 2006 Dec 1.

44.

Role of exon-16-deleted HER2 in breast carcinomas.

Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S.

Endocr Relat Cancer. 2006 Mar;13(1):221-32.

PMID:
16601290
45.

Diadenosines as FHIT-ness instructors.

Campiglio M, Bianchi F, Andriani F, Sozzi G, Tagliabue E, Ménard S, Roz L.

J Cell Physiol. 2006 Aug;208(2):274-81. Review.

PMID:
16547961
46.

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.

J Cell Physiol. 2006 May;207(2):420-7.

PMID:
16419029
47.

Apoptosis induction by trastuzumab: possible role of the core biopsy intervention.

Ménard S, Pupa SM, Campiglio M, Balsari A, Fagnoni F, Costa A, Tagliabue E.

J Clin Oncol. 2005 Oct 1;23(28):7238-40. No abstract available. Erratum in: J Clin Oncol. 2006 Jan 20;24(3):531. Campiglio, Manuella [corrected to Campiglio, Manuela]; Taglibue, Elda [corrected to Tagliabue, Elda].

PMID:
16192615
48.

Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?

Normanno N, Campiglio M, Perrone F, De Luca A, Menard S.

Ann Oncol. 2005 Oct;16(10):1709. Epub 2005 Sep 8. No abstract available.

PMID:
16150806
49.

MicroRNA gene expression deregulation in human breast cancer.

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM.

Cancer Res. 2005 Aug 15;65(16):7065-70.

50.

The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1.

Berno V, Porrini D, Castiglioni F, Campiglio M, Casalini P, Pupa SM, Balsari A, Ménard S, Tagliabue E.

Endocr Relat Cancer. 2005 Jun;12(2):393-406.

PMID:
15947111

Supplemental Content

Loading ...
Support Center